Cardiovascular Risk Profile in Prostate Cancer Patients Treated with GnRH Agonists versus Antagonists: An Italian Real-World Analysis.

Valentina PerroneLuca Degli EspostiElisa GiacominiChiara VeronesiValerio BliniMarco Oderda

Published in: Therapeutics and clinical risk management (2020)

This Italian observational study shows that most patients received a GnRH agonist rather than a GnRH antagonist prescription. GnRH antagonist seems to have a better CV risk profile than GnRH agonist, both in patients with and without a history of CV events.

Keyphrases

prostate cancer
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis